Poultry & Pig Vaccine Manufacturer with Strong R&D

You are here: Home » About Us » Our Company

Company Profile

Vland Animal Health Science and Technology Industrial Park is located on Keyun Road, High-tech Zone, Qingdao City, Shandong Province, China and is affiliated with Qingdao Vland Biotech Co., Ltd. The project broke ground in October 2020 and was completed and put into operation in June 2022. Covering an area of 79333 ㎡, the entire industrial park consists of 10 single buildings with a total floor area of approximately 138,000 ㎡, with a total investment of 1 billion Chinese yuan.

The industrial park possesses four business segments, including:

VLAND Animal Health Group

We passed the acceptance inspection of the new version of Veterinary GMP by the Ministry of Agriculture and Rural Affairs in June 2022, with 9 production lines for live vaccines, inactivated vaccines and antibodies.

KDN Pharmaceutical

We passed the acceptance inspection of the new version of Veterinary GMP by the Ministry of Agriculture and Rural Affairs in May 2022, with 17 pharmaceutical drug production lines and 4 feed additive production lines.

Provide-Third-party-Services-For-the-Industry

National Research Center for Animal Health Care Products

We conduct research on innovative drugs, improved new veterinary drugs, formulation processes, etc., and provide comprehensive third-party testing services for the industry.

VLAND Queen’s Pet

We are committed to providing standardized, safe and effective pet-specific drugs, health care products, medical devices, consumables and professional services for the field of pet medical care.

Qingdao Vland Animal Health Platform regards animal health, green production and quality management as our core responsibilities and is committed to promoting the development of the global animal health industry.

THE MORE RESEARCH WE DO, THE BETTER VLAND WE ARE.

Vland Animal Health currently has 108 full-time R&D technicians, including 11 PhDs and 62 master’s degree holders. Personnel with master’s degrees or above account for 67.6%.
We possess multiple national-level technological innovation platforms, such as the National Enterprise Technology Center, National Research Center for Animal Health Care Products, Key Laboratory of Animal Health Products Engineering and Technology of the Ministry of Agriculture and Rural Affairs, and Postdoctoral Research Station.
With 73 authorized invention patents (including 1 U.S. patent and 1 PCT international application), and 46 national new veterinary drug certificates (including 3 Class-I national new veterinary drugs), our R&D capabilities rank among the top in the animal health industry.

Qingdao Vland Animal Health Group Co., Ltd.

Our comprehensive production workshop cover a construction area of approximately 25,000㎡, the warehouse center about 7,300㎡, and the experimental animal house 2,500㎡.
Having passed the acceptance of the new version of Veterinary GMP by the Ministry of Agriculture and Rural Affairs in June 2022, we possess 9 production lines, encompassing animal vaccine and antibody production lines of different target animals, along with supporting facilities such as a quality control center, experimental animal house, and R&D center. We are capable of producing poultry and swine vaccines, antibodies, etc., with an annual output of 20 billion doses of vaccines.

Embryo Culture Live Viral Vaccines
Cell Culture Live Viral Vaccines
Cell Suspension Culture Live Viral Vaccines
Live Bacterial Vaccines
Embryo Culture Inactivated Viral Vaccines
Cell Culture Inactivated Viral Vaccines
Cell Suspension Culture Inactivated Viral Vaccines
Inactivated Bacterial Vaccines (including Bacterial Culture Subunit Vaccines)
Egg Yolk Antibodies

Qingdao KDN Animal Pharmaceutical Co., Ltd.

Our comprehensive production workshop covers a construction area of approximately 22,000㎡, the solid disinfectant workshop about 770㎡, and the liquid disinfectant workshop around 2,000㎡.
Having passed the acceptance of the new version of Veterinary GMP by the Ministry of Agriculture and Rural Affairs in May 2022, we have 17 pharmaceutical drug production lines and 4 feed additive production lines, with an annual output of 200,000 tons of various solid and liquid products.

Powders/Premixes
Granules
Oral Solutions
Liquid Disinfectants
Liquid Insecticides
Non-terminally Sterilized Large/Small Volume Injections
Terminally Sterilized Large Volume Non-intravenous Injections
Terminally Sterilized Small Volume Injections
Solid Disinfectants
Mixed Feed Additives
Additive Premixed Feeds

National Research Center for Animal Health Care Products

Our national research center currently has 57 full-time R&D personnel, including 9 PhDs, with those holding a master’s degree or above accounting for 75%.
The R&D laboratory building covers a construction area of approximately 8,100㎡, and the experimental animal house 2,500㎡.
Our research center houses testing laboratories, veterinary biological products laboratories, and a veterinary drug technology center. The center is responsible for:

The R&D and industrialization of innovative drugs, improved drugs, generic drugs, as well as feed additives, veterinary vaccines, antibodies, and biological preparations
Providing comprehensive third-party testing services for the industry.

Mission and Vision

Value

The value of top competitiveness

Learning

Innovating through learning

Aspiration

Inspiring the aspiration of every maker

Network

An ecological network of co-creation and win-win

Doing

Excellent capability in doing

Mission

Vland Animal Health adheres to the business philosophy of technological innovation, value marketing, and collaborative development. Guided by the management philosophy of building a simple, rational, and people-oriented organization, we strive to become a world-class high-tech manufacturer in animal health products. Committed to advanced biotechnology R&D and production, we aim to deliver premier products and services globally in the fields of animal health and pet healthcare.

Vision

Vland Animal Health will always prioritize technological innovation as our core driver, align with customer needs, and shoulder ecological responsibility. We aspire to become a global leader in animal health and pet healthcare solutions, providing core technological support for bio-product manufacturing and green solutions for food safety. Through the power of biotechnology, we aim to create value for animal health, ecological sustainability, and human well-being.

Our History

1998
2008
2013
2014
2019
2020
2022
2023
2023

Qingdao Vland Animal Health Group Co., Ltd., formerly known as “QINGDAO BOITECH BIOPHARMACEUTICAL CO., LTD.”, was founded
QINGDAO BOITECH BIOPHARMACEUTICAL CO., LTD. entered into a cooperation with Qingdao KDN Pharmaceutical Co., Ltd. and became its wholly-owned subsidiary.
Qingdao KDN Pharmaceutical Co., Ltd. merged with Qingdao KDN Biotechnology Co., Ltd. to form Qingdao Vland Biotech Co., Ltd.
QINGDAO BOITECH BIOPHARMACEUTICAL CO., LTD. was renamed “Qingdao Vland Biological Products Co., Ltd.”
Qingdao Vland Biotech Co., Ltd. (the parent company) was listed on the main board of the Shanghai Stock Exchange, with the stock code 603739.
The construction of Qingdao Vland Animal Health Science and Technology Industrial Park broke ground.
Qingdao Vland Animal Health Science and Technology Industrial Park was completed and put into operation; meanwhile, Qingdao Vland Animal Health Group Co., Ltd. and Qingdao KDN Animal Pharmaceutical Co., Ltd. passed the acceptance inspection of the new version of Veterinary GMP by the Ministry of Agriculture and Rural Affairs.
“Qingdao Vland Biological Products Co., Ltd.” was renamed “Qingdao Vland Animal Health Group Co., Ltd.”
Qingdao Vland Animal Health Group Co., Ltd., Qingdao KDN Animal Pharmaceutical Co., Ltd., and Qingdao Vland Queen’s Pet moved into Qingdao Vland Animal Health Science and Technology Industrial Park, jointly forming the Qingdao Vland Animal Health Platform.

Factory Tour

Qingdao Vland Animal Health Science and Technology Industrial Park covers a total floor area of 116,495.23 square meters. The industrial park houses 9 vaccine and antibody production lines with an annual output of 23 billion doses of animal vaccines, 17 chemical veterinary drug production lines, and 4 feed additive production lines with an annual output of 200,000 tons of various solid and liquid products.

The industrial park consists of 10 individual buildings:

Building 1: Serves as the administrative service center for the industrial park and the quality control center for biological products.
Building 2: Functions as the R&D building for the National Research Center for Animal Health Care Products, focusing on innovative drugs, improved veterinary drugs, and formulation process research. It also provides comprehensive third-party testing services for the industry.
Building 3: The production workshop of Qingdao Vland Animal Health Group Co., Ltd., which passed the GMP certification by the Ministry of Agriculture and Rural Affairs in June 2022. The first floor is dedicated to antibody production, while the second and third floors in the southern area house live vaccine production lines, and those in the northern area are for inactivated vaccine production.
Building 4: Serves as the warehousing center for Vland biological products.
Building 5: An experimental animal facility licensed for animal testing, supporting R&D and product validation for the engineering center and the company.
Building 6: The main production workshop of Qingdao KDN Animal Pharmaceutical Co., Ltd., which passed the new-version Veterinary GMP certification in May 2022. With four stories and high automation, the workshop’s 21 production lines are efficiently operated by only 30 workers, ensuring stable product quality and sufficient supply to meet international client demands.
Building 7: Reserved for a traditional Chinese medicine extraction workshop.
Building 8: Dedicated to solid disinfectant production.
Building 9: Used for liquid disinfectant and insecticide production.
Building 10: Functions as a reagent warehouse.

Our Experts

Professor Zhao Jun

Professor Zhao Jun, Ph.D., Master’s/Doctoral Supervisor, Director of the Poultry Disease Research Institute of Henan Agricultural University, Leader of the Science and Technology Innovation Team in Henan Colleges and Universities, Science and Technology Innovation Talent in Henan Colleges and Universities, and High-Level Entrepreneurial and Innovative Talent of the 4th “Hundred Talents Program” in Fujian Province.

In undergraduate teaching, he teaches core courses for the Animal Quarantine and Veterinary Medicine programs. In graduate teaching, he organizes and is responsible for the courses Topics on Infectious Diseases and Biological Products and Progress in Preventive Veterinary Medicine.

His research focuses on new technologies for the prevention and control of animal diseases, including the establishment of reverse genetic systems for major animal disease pathogens and research on their pathogenic mechanisms, the construction of recombinant combined and polyvalent genetic engineering vaccines using reverse genetic technology, large-scale antigen preparation, the construction and large-scale culture of homologous cell lines, and rapid diagnostic technologies for animal diseases.

Professor Song Guicai

Professor Song Guicai, Ph.D., a Taishan industry Leading Talent, an External Review Expert of the Ministry of Industry and Information Technology, an External Consulting Expert of the Chinese Academy of Engineering, and a member of the Academic Committee of the Key Laboratory of Animal Biosafety Risk and Prevention and Control of the Ministry of Agriculture and Rural Affairs. He also serves as a Visiting Professor at Jilin Agricultural Science and Technology College and Liaoning Agricultural Vocational and Technical College, as well as an Off-Campus Graduate Supervisor at Southwest Minzu University, Northwest A&F University, and Harbin Veterinary Research Institute.

He has published 29 papers at home and abroad, and participated in compiling and edited 3 professional textbooks. He was the first to adapt adherent MDCK cells and avian LMH cells into suspension cells, accomplishing the large-scale culture and industrialization of highly pathogenic avian influenza virus and avian adenovirus in MDCK and LMH suspension cells. In the past five years, he has presided over and participated in 6 projects at or above the provincial level in Shandong Province. The project “Research and Demonstration of Key Technologies for Large-Scale Fully Suspension Culture of Avian Influenza Virus in Cells” presided over by him was rated as “Internationally Advanced Level” by the China High-Tech Industrialization Association.

Professor Liu Guangqing

Professor Liu Guangqing, Ph.D., Researcher, Doctoral Supervisor, and Chief Scientist of the Companion Animal Biosafety Risk Early Warning and Prevention Technology Team. He is currently an “Agricultural Science Talent” Innovative Leading Talent of the Chinese Academy of Agricultural Sciences, a Shanghai Agricultural Leading Talent, Executive Director of the National Special Economic Animal Science and Technology Innovation Alliance, and Director of the Veterinary Public Health Branch of the Chinese Association of Animal Science and Veterinary Medicine.

He has long been committed to: (1) research on the pathogenic mechanism of pet viruses and new vaccines; (2) research on the detection, prevention and control technologies of pet infectious diseases and emerging infectious diseases; (3) research and development as well as application of cytokines such as interferons and interleukins for pets. He has presided over and participated in more than 20 scientific research projects, including the National Natural Science Foundation of China, sub-projects of the National Key Research and Development Program, and provincial and ministerial-level projects. In recent years, he has published more than 100 academic papers in academic journals such as PLoS Pathogens, JVI, JBC, ACS Nano, JGV, Transbound Emerg Dis, Vet Microbiol, Virus Res, and Chinese Science Bulletin. He has presided over the compilation of 2 monographs, obtained 6 authorized invention patents, won 1 Shanghai Science and Technology Award and 2 Zhejiang Provincial Science and Technology Progress Awards, and trained more than 70 doctoral and master's students.

Dr. Wu Jiaqiang

Dr. Wu Jiaqiang, Researcher, currently serves as Member of the Party Committee and Vice President of Shandong Academy of Agricultural Sciences. He also holds concurrent positions including Standing Committee Member of Shandong Association for Science and Technology, and Director of the Animal Infectious Diseases Branch of the Chinese Association of Animal Science and Veterinary Medicine. He was selected as a Taishan Scholar Distinguished Expert in 2015, included in the National Innovation Talent Advancement Program in 2017, chosen for the Leading Talent of the National Special Support Program for High-Level Talents in 2018, elected as Chief Expert of Shandong Swine Industry Technology System in 2019, and received renewal support after being rated “Excellent” in the assessment for Taishan Scholar Distinguished Expert in 2021. He has been awarded a Second-Class Merit once.

He has been engaged in research on animal disease prevention and control as well as the development of new vaccines for over 20 years. He has developed rapid diagnosis and immune prevention technologies for swine diseases, established a comprehensive prevention and control technology system for swine diseases, and achieved major breakthroughs in the comprehensive prevention and control of swine reproductive disorders and viral diarrhea. These contributions have played an important role in ensuring stable production, supply guarantee and high-quality development of Shandong’s swine industry.

He has published more than 170 academic papers (including over 70 SCI papers) in journals such as J Mater Chem A, Emerg Infect Dis, and J Immunol, and has edited and published 9 books. He holds more than 30 authorized invention patents and has formulated 15 national standards, local standards and provincial key promoted technologies. The independently developed “Haemophilus parasuis Bivalent Inactivated Vaccine”, and the jointly developed products such as “Porcine Transmissible Gastroenteritis-Porcine Epidemic Diarrhea Bivalent Live Vaccine” and “Diclofenac Sodium Injection” have passed national audit. He has obtained 6 national new veterinary drug registration certificates, 6 production licenses, and 6 clinical trial approvals from the Ministry of Agriculture. These technologies and products have been transferred to more than 10 large-scale animal health product enterprises, and the developed prevention and control products and technologies have been promoted and applied to a total of over 100 million pigs in more than 20 major livestock-producing areas across the country.

He has presided over and undertaken major scientific research projects (topics) such as the National Natural Science Foundation of China, the National Key Research and Development Program, and the National Science and Technology Support Program, and has won 14 provincial (ministerial) and above-level scientific and technological achievements. The main achievements are as follows:

“Establishment and Application of a Prevention and Control Technology System for Major Swine Reproductive Disorders” won the Second Prize of the National Science and Technology Progress Award;
“Molecular Genetic Variation, Diagnosis and Systematic Prevention and Control Technology of Porcine Reproductive and Respiratory Syndrome (PRRS) Pathogens” and “R&D and Application of New Prevention and Control Technologies for Four Important Swine Diseases” won the First Prize of Shandong Provincial Science and Technology Progress Award;
The authorized invention patent “A Haemophilus parasuis Strain LC and Its Application” won the First Prize of Shandong Provincial Patent Award and the Excellent Award of China Patent Award;
The authorized invention patent “A Testing Kit for Haemophilus parasuis and Its Testing Method” won the First Prize of Shandong Provincial Patent Award;
“R&D, Demonstration and Promotion of Key Technologies for Prevention and Control of Important Swine Diseases” won the Second Prize of Shennong China Agricultural Science and Technology Award.

Company Profile

VLAND Animal Health Group

KDN Pharmaceutical

National Research Center for Animal Health Care Products

VLAND Queen’s Pet

THE MORE RESEARCH WE DO, THE BETTER VLAND WE ARE.

Qingdao Vland Animal Health Group Co., Ltd.

Qingdao KDN Animal Pharmaceutical Co., Ltd.

National Research Center for Animal Health Care Products

Mission

Vision

Factory Tour

Professor Zhao Jun

Professor Song Guicai

Professor Liu Guangqing

Dr. Wu Jiaqiang

Quick Links

Products